TY - JOUR
T1 - Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: Animal models and translation to human clinical trials
AU - Banga, J. Paul
AU - Nielsen, Claus H.
AU - Gilbert, Jacqueline A.
AU - El Fassi, Daniel
AU - Hegedus, Laszlo
PY - 2008/9/1
Y1 - 2008/9/1
N2 - Most current approaches for treating Graves' disease are based essentially upon regimes developed nearly 50 years ago. Moreover, therapeutic approaches for complications such as thyroid-associated ophthalmopathy (TAO) and dermopathy are singularly dependent on conventional approaches of nonspecific immunosuppression. The recent development of an induced model of experimental Graves' disease, although incomplete as it lacks the extrathyroidal manifestations, provided opportunities to investigate immune intervention strategies, including influence upon the autoreactive B and T cell players in the autoimmune process. These major advances are generating new possibilities for therapeutic interventions for patients with Graves' disease and TAO.
AB - Most current approaches for treating Graves' disease are based essentially upon regimes developed nearly 50 years ago. Moreover, therapeutic approaches for complications such as thyroid-associated ophthalmopathy (TAO) and dermopathy are singularly dependent on conventional approaches of nonspecific immunosuppression. The recent development of an induced model of experimental Graves' disease, although incomplete as it lacks the extrathyroidal manifestations, provided opportunities to investigate immune intervention strategies, including influence upon the autoreactive B and T cell players in the autoimmune process. These major advances are generating new possibilities for therapeutic interventions for patients with Graves' disease and TAO.
UR - http://www.scopus.com/inward/record.url?scp=51849091132&partnerID=8YFLogxK
U2 - 10.1089/thy.2007.0406
DO - 10.1089/thy.2007.0406
M3 - Conference paper
VL - 18
SP - 973
EP - 981
JO - Thyroid
JF - Thyroid
IS - 9
T2 - Symposium on Thyroid Associated Ophthalmopathy
Y2 - 17 November 2006 through 18 November 2006
ER -
